The latest data point for CVS's Return on Sales (ROS) in Q4'25 stands at 2.04%, marking a recovery from the negative territory observed in the prior quarter. This value reflects a modest improvement in profitability margins for the period ending December 31, 2025, amid ongoing operational challenges. Over the timeframe from Q1'23 to Q4'25, CVS's ROS has exhibited a volatile and generally declining trend, fluctuating between a high of 4.13% in Q3'23 and a low of -2.61% in Q3'25, with an overall average around 2.3%. Notable declines occurred in Q1'24 (2.58%) and Q3'24 (0.91%), followed by a sharp drop into negative values in Q3'25, before rebounding in Q4'25; this pattern suggests persistent pressures on margins, potentially from cost increases or competitive dynamics in the healthcare sector, warranting close monitoring for sustained recovery.